Shifting FcγRIIA-ITAM from activation to inhibitory configuration ameliorates arthritis

Sanae Ben Mkaddem,1,2,3,4 Gilles Hayem,5 Friederike Jönsson,6,7 Elisabetta Rossato,1,2,3,4 Erwan Boedec,1,2,3,4 Tarek Boussetta,1,2,3,4 Jamel El Benna,1,2,3,4 Pierre Launay,1,2,3,4 Jean-Michel Goujon,8 Marc Benhamou,1,2,3,4 Pierre Bruhns,6,7 and Renato C. Monteiro1,2,3,4

Rheumatoid arthritis–associated (RA-associated) inflammation is mediated through the interaction between RA IgG immune complexes and IgG Fc receptors on immune cells. Polymorphisms within the gene encoding the human IgG Fc receptor IIA (hFcγRIIA) are associated with an increased risk of developing RA. Within the hFcγRIIA intracytoplasmic domain, there are 2 conserved tyrosine residues arranged in a noncanonical immunoreceptor tyrosine–based activation motif (ITAM). Here, we reveal that inhibitory engagement of the hFcγRIIA ITAM either with anti-hFcγRII F(ab′)2 fragments or intravenous hIgG (IVIg) ameliorates RA-associated inflammation, and this effect was characteristic of previously described inhibitory ITAM (ITAMi) signaling for hFcRγ and hFcγRIIIA, but only involves a single tyrosine. In hFcγRIIA-expressing mice, arthritis induction was inhibited following hFcγRIIA engagement. Moreover, hFcγRIIA ITAMi-signaling reduced ROS and inflammatory cytokine production through inhibition of guanine nucleotide exchange factor VAV-1 and IL-1 receptor–associated kinase 1 (IRAK-1), respectively. ITAMi signaling was mediated by tyrosine 304 (Y304) within the hFcγRIIA ITAM, which was required for recruitment of tyrosine kinase SYK and tyrosine phosphatase SHP-1. Anti-hFcγRII F(ab′)2 treatment of inflammatory synovial cells from RA patients inhibited ROS production through induction of ITAMi signaling. These data suggest that shifting constitutive hFcγRIIA-mediated activation to ITAMi signaling could ameliorate RA-associated inflammation.

Introduction

Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease. Neutrophils, lymphocytes, mast cells, macrophages, synovial tissue cells, and platelet microparticles present in the inflamed synovium have been implicated in RA pathophysiology (1, 2). Circulating autoantibodies are present in a majority of RA patients, and joint tissue is frequently covered with immune complexes (ICs) (3, 4) mainly composed of rheumatoid factors and ICs formed of anticyclic citrullinated peptide (anti-CCP) IgG antibodies and CCP.

RA IgG ICs bind to IgG Fc receptors (FcγRs) that play an essential role in disease progression. Neutrophils and monocytes are FcγR-bearing cells that contribute to joint inflammation via the release of inflammatory mediators that increase vascular permeability and promote further immune cell recruitment (1). There are 3 main classes of human FcγRs (hFcγRs): hFcγRI (CD64), hFcγRII (CD32), and hFcγRIII (CD16). They differ in function, cell distribution, and IgG-binding capacity (5). Three isoforms of hFcγRII have been identified: hFcγRIIA, hFcγRIIB, and hFcγRIIC. Among them, hFcγRIIA is a potent activator of inflammation. hFcγRIIA is expressed by all myeloid cells and platelets. hFcγRIIA possesses an immunoreceptor tyrosine–based activation motif (ITAM) in its intracytoplasmic domain and, in contrast with hFcγRI and hFcγRIIIA, is not associated with the ITAM-bearing subunit FcγR (6–8). hFcγRIIA is a low-affinity receptor that interacts with all 4 human IgG subclasses (9) as well as mouse IgG1, IgG2a, and IgG2b (10). There is no FcγRIIA homolog in the mouse (5). Cross-linking of hFcγRIIA by IgG ICs results in the phosphorylation of ITAM tyrosines residues, followed by recruitment and activation of the tyrosine kinase Syk. This leads to calcium mobilization, activation of MAPK pathways, activation of NF-κB, and inflammatory cell activation (11). Two codominantly expressed alleles of hFcγRIIA differ by an arginine or a histidine at amino acid position 131 and by their affinity for hIgG2 (10). There are no FcγRIIA homolog in the mouse (5). The hFcγRIIA-H131 variant is the only IgG receptor that efficiently binds human IgG2 (12). The hFcγRIIA-R131 variant is associated with an increased risk of developing RA (13). Transgenic expression of hFcγRIIA-R131 on neutrophils and monocytes of mice lacking endogenous activating FcγR (due to ablation of the FcγR chain gene that is required for mFcγRI, mFcγRII, mFcγRIII, and mFcγRI expression) restores susceptibility to autoimmune diseases and passive proinflammatory reactions (14). Most interestingly, hFcγRIIA-R131 transgenic mice are highly susceptible to both collagen-induced arthritis (CIA) and collagen antibody–induced arthritis (CAIA) and spontaneously develop multisystem autoimmune diseases (15).

FcγRIIB, which is conserved in mice and humans, is a single-chain inhibitory FcγR. FcγRIIB contains a tyrosine-based inhibition motif (ITIM) in its cytoplasmic region (16). Inhibition is...
dependent on the isotype of IgG and on FcγRIIB expression levels. The classic concept of the functional polarity of ITIM and ITAM motifs has been recently reevaluated. Several studies have demonstrated that ITAM can also initiate inhibitory signaling toward heterologous receptors. This active inhibitory signaling by ITAM-bearing receptors is called inhibitory ITAM (ITAMI) (17–19). Thus, the human IgA receptor hFcαRII, which is associated with FcγRI, acts as a bifunctional module that, depending on the type of interaction with its ligand, induces either activating or inhibitory cell signaling (18). Although multivalent crosslinking of hFcαRI with IgA ICs induced proinflammatory signaling (20), monovalent targeting of hFcαRI with monomeric IgA (or Fab anti-FcαRII) in the absence of antigen can trigger inhibitory signals toward a whole array of cellular functions such as IgG-dependent phagocytosis and TLR- or cytokine-mediated responses (21, 22). Strikingly, monovalent targeting of hFcαRI (termed “ITAMI configuration”) induces weak ITAM phosphorylation of the FcγR subunit and transient recruitment of Syk following by stable recruitment of the tyrosine phosphatase SHP-1, whereas multivalent aggregation of the receptor promotes strong ITAM phosphorylation with stable Syk recruitment. Recruitment of SHP-1 in the ITAMI configuration promotes the actin depolymerization-dependent “trapping” of hFcαRI and of the targeted activating receptors within the same lipid rafts, followed by the appearance of intracellular clusters called inhibosomes (23). Recently, we demonstrated that hFcγRIIIB (CD16A), which is also associated with the common FcγRI subunit, was similarly able to induce ITAMI signaling following interaction with hIgG, i.e. hIgG (IVIg), or F(ab′)2 fragments of the anti-FcγRIIIB mAb 3G8 (24).

Here, we explored whether one could shift hFcγRIIB activation from ITAM signaling toward ITAMI signaling as a relevant therapeutic strategy in RA using transgenic mice expressing hFcγRIIIB-R131. Anti-hFcγRIIB F(ab′)2 fragments or IVIg prevented RA development in these mice. The inhibitory mechanism was elucidated as induction of ITAMI signaling by hFcγRIIB independently of mFcγRIIB. Importantly, hFcγRIIIB ITAMI signaling reversed the inflammatory phenotype of human synovial fluid-infiltrating cells from RA patients. Thus, switching hFcγRIIB from ITAM to ITAMI signaling opens new therapeutic perspectives in RA.

**Results**

**Prevention of arthritis development in transgenic mice expressing hFcγRIIB following anti-hFcγRII F(ab′)2 or IVIg treatment.** We first analyzed the effect of F(ab′)2 fragments of anti-hFcγRII mAb AT-10 on the development of CAIA in WT mice transgenic for hFcγRIIIB-R131. mAb AT-10 is specific for hFcγRII, as compared with the monodonal antibody IV.3, which specifically recognizes hFcγRII and not hFcγRIIB (Supplemental Figure 1; supplemental material available online with this article; doi:10.1172/JCI74572DS1). AT-10 F(ab′)2 treatment strongly inhibited arthritis development in transgenic mice expressing hFcγRIIB (hereafter referred to as hFcγRIIBΔ), but not in WT mice (Figure 1, A–E). Treatment with an irrelevant F(ab′)2 (clone 320) had no effect. Noticeably, AT-10 F(ab′)2 treatment reduced CAIA-induced ankle thickening to one-third of the level reached in WT mice (Figure 1C), implying that hFcγRIIB targeting might not only block potential deleterious activation of hFcγRIIB but might also counteract the activation triggered by the endogenous FcyRs. Morphological signs of cartilage destruction, synovitis, and pannus formation were significantly reduced in hFcγRIIBΔ mice by AT-10 F(ab′)2 treatment (Figure 1D).

To exclude the role of the endogenous activating (ITAM-bearing) FcγRs, the same experiments were performed in transgenic mice that express hFcγRIIB on the FcγR−/− background (having a geno-type of FcγR1−/− FcγR2b−/− FcγR3a−/− FcεRI−/− FcepsilonRI2−/−, hereafter referred to as hFcγRIIBΔ-FcγR−/− mice). Upon CAIA induction, hFcγRIIBΔ-FcγR−/− mice, but not FcγR−/− mice, fully developed arthritis (Figure 1, F and G), confirming the role of hFcγRIIB as a proinflammatory receptor in arthritis development as reported by others (25). In contrast, anti-hFcγRII AT-10 F(ab′)2, or a specific anti-hFcγRIIB IV.3 F(ab′)2, but not irrelevant F(ab′)2 treatment significantly inhibited arthritis development, as shown morphologically (Figure 1F and Supplemental Figure 2A) and by reduced ankle thickening (Figure 1G and Supplemental Figure 2B). Human IVIg similarly reduced arthritis development. More importantly, AT-10 F(ab′)2-treated mice recovered rapidly from their low-score disease, whereas, within the time frame of the experiment, the disease reached a high-score plateau in control mice treated with irrelevant F(ab′)2. This was accompanied by a significant reduction in leukocyte infiltration in the joints of hFcγRIIBΔ mice, particularly neutrophils and monocytes, as compared with WT mice (Figure 2, A–D).

To examine whether hFcγRIIB targeting inhibited chemotaxis of inflammatory leukocytes, we analyzed in vitro the transmigration of BM-derived macrophages (BMM). AT-10 F(ab′)2 treatment of BMM from hFcγRIIBΔ-FcγR−/− mice induced transmigration induced by MCP-1 (Figure 2E). As MCP-1 can also be produced by monocytes/macrophages, we examined the effect of AT-10 F(ab′)2 treatment on MCP-1 production by LPS-activated BMM. This production was also inhibited (Figure 2F). These findings suggest that AT-10 F(ab′)2 treatment might prevent both monocyte recruitment and activation of recruited monocytes, thereby blocking an inflammation-aggravating loop. This may explain, at least in part, the prevention of the development of arthritis in AT-10 F(ab′)2-treated hFcγRIIBΔ mice.

hFcγRIIB mediates ITAMI signaling that relies on the ITAM distal tyrosine. To identify the mechanism through which hFcγRIIB targeting prevented arthritis development, we used BMM from hFcγRIIBΔ-FcγR−/− and FcγR−/− mice. Treatment of hFcγRIIBΔ-FcγR−/− BMM with AT-10 F(ab′)2, or with IVIg induced a transient recruitment (up to 30 minutes) of the protein tyrosine kinase Syk to hFcγRIIB, which was followed by stable recruitment (up to at least 6 hours) of the protein tyrosine phosphatase SHP-1 (Figure 3, A and B). These recruitments were accompanied by the concomitant phosphorylation of SHP-1. Neither AT-10 F(ab′)2 nor IVIg induced Syk or SHP-1 recruitment in the absence of FcγRIIA (Figure 3, C and D). To analyze whether this signaling plays a role in the regulation of inflammation, we tested the effect of AT-10 F(ab′)2 and IVIg on the production of cytokines induced by LPS. Treatment of BMM with AT-10 F(ab′)2, or with IVIg inhibited the production of TNF-α, IL-6, and MIP-2 in hFcγRIIBΔ-FcγR−/− BMM but not in FcγR−/− BMM (Figure 3E). We confirmed these results using F(ab′)2 fragments of anti-hFcγRIIB mAb IV.3 (Supplemental Figure 2, C and D). This was associated with the inhibition of ROS production induced by N-formyl-methionine-leucine-phenylalanine (MLF) from hFcγRIIBΔ-FcγR−/− BMM but not from FcγR−/−
Figure 1. Blocking F(ab′)_2 fragments anti-hFcγRII or IVlg reduces edema and erythema as well as histological aspects of synovial hyperplasia in transgenic hFcγRIIA mice subjected to the CAIA model. (A) Arthritis protocol is shown. Mice were treated every 2 days with AT-10 F(ab′)_2 or with an irrelevant mAb 320 F(ab′)_2 (100 μg/20 g mouse) or IVlg (20 mg/20 g mouse) after disease induction by i.v. injection of an anti-CII mAb plus LPS. (B) Representative images of hind paws from WT (top panels) and hFcγRIIA Tg (bottom panels) mice at day 10. (C) Arthritis was evaluated by measuring the increase in ankle thickness (mm). Bars show mean ± SEM. (D) Microscopy analysis of H&E-stained tissue sections from ankles obtained from representative mice. Scale bars: 200 μm. (E) The inflammation scores were graded blind as follows: 0 (normal), 1 (mild), 2 (moderate), or 3 (severe). (F) Representative images of hind paws from FcRγ−/− (top panels) and FcγRIIA Tg−FcRγ−/− mice (bottom panels) at day 10 after the initial injection of anti-CII mAb. (G) Arthritis was evaluated by measuring the increase in ankle thickness (mm). *P < 0.05; n = 5.
BMM (Supplemental Figure 2E). Thus, targeting of hFcγRIIA on mouse BMM induced ITAMi signaling responsible for inhibition of an inflammatory response such as the one observed during arthritis development in mice.

To determine whether targeting of hFcγRIIA could induce inhibitory signaling in human monocytes, we used the THP-1 monocytic cell line transfected with hFcγRIIA-R131 (THP-1-FcγRIIA-R131−CD14+) (26). These cells express hFcγRI and hFcγRIIB but neither hFcγRIIB nor hFcγRIII (Figure 4A). Whereas targeting of hFcγRIIA with Fab fragments of AT-10 did not induce any signaling (data not shown), preincubation of the cells with AT-10 F(ab′), induced a transient recruitment of the tyrosine kinase Syk to hFcγRIIA, followed by stable recruitment and tyrosine phosphorylation of the tyrosine phosphatase SHP-1 (Figure 4B). No recruitment of the SH2-con-
of which are conserved tyrosine residues arranged in a noncanonical ITAM, we explored whether the hFcγRIIA inhibitory signal was dependent on the hFcγRIIA-ITAM tyrosine residues. We transfected the rat basophilic leukemia cell line RBL-2H3 with WT hFcγRIIA or with hFcRIIA mutated on each of the 3 intracellular tyrosine residues. All transfectants expressed significant levels of the respective hFcγRIIA mutants at the cell surface (Figure 5A and Supplemental Figure 4A). As expected, targeting of transfectants expressing WT hFcγRIIA with AT-10 F(ab′)$_2$ resulted in sequential recruitment of Syk and SHP-1 to the receptor (Figure 5B). AT-10 F(ab′)$_2$ treatment also induced inhibition of cell activation triggered by a nontargeted activating receptor. Indeed, degranulation ($\beta$-hexosaminidase release) induced upon crosslinking of the containing 5-inositol phosphate phosphatase SHIP1 to hFcγRIIA was observed. Confirming the role of hFcγRIIA in Syk and SHP-1 recruitment in these cells, silencing FCGR2A mRNA (encoding hFcγRIIA) abolished Syk and SHP-1 recruitment (Figure 4C). A control siRNA had no effect (Supplemental Figure 3). Silencing Syk expression (Figure 4D) impaired the recruitment of SHP-1 to hFcγRIIA induced by AT-10 F(ab′)$_2$ (Figure 4E). Together, these findings suggest that in hFcγRIIA, targeting by AT-10 F(ab′)$_2$ induced an inhibitory signaling pathway (independently of FcγRIIB) sequentially involving Syk and SHP-1, as previously described for ITAMi signaling of Fc receptors (24).

Because hFcγRIIA is a single-transmembrane (single-TM) receptor possessing 3 tyrosine residues in its cytoplasmic tail, 2 of which are conserved tyrosine residues arranged in a noncanonical ITAM, we explored whether the hFcγRIIA inhibitory signal was dependent on the hFcγRIIA-ITAM tyrosine residues. We transfected the rat basophilic leukemia cell line RBL-2H3 with WT hFcγRIIA or with hFcRIIA mutated on each of the 3 intracellular tyrosine residues. All transfectants expressed significant levels of the respective hFcγRIIA mutants at the cell surface (Figure 5A and Supplemental Figure 4A). As expected, targeting of transfectants expressing WT hFcγRIIA with AT-10 F(ab′)$_2$ resulted in sequential recruitment of Syk and SHP-1 to the receptor (Figure 5B). AT-10 F(ab′)$_2$ treatment also induced inhibition of cell activation triggered by a nontargeted activating receptor. Indeed, degranulation ($\beta$-hexosaminidase release) induced upon crosslinking of the

Figure 3. hFcγRIIA targeting by anti-hFcγRII F(ab′)$_2$ or IVIg induces SHP-1–dependent inhibitory signaling that blocks LPS-induced proinflammatory cytokine production by mouse macrophages. BMM from hFcγRIIA$^{–/–}$ FcγRII– A or B) or FcγRIIB– C or D) mice were incubated with either AT-10 anti-hFcγRII F(ab′)$_2$_(10 μg/ml; A and C) or IVIg (10 mg/ml; B and D) for the indicated times at 37°C. Cells were solubilized in 1% digitonin lysis buffer and immunoprecipitated with AT-10 (IP: FcγRII). Eluted proteins were immunoblotted (IB) with antibodies of the indicated specificities. Total lysates were analyzed likewise by immunoblotting. (E) Cytokine production: 2 × 10$^6$ BMM from hFcγRIIA$^{–/–}$ FcγRIIB– or FcRIIB– mice were pretreated, or not, with AT-10 F(ab′)$_2$(10 μg/ml) or IVIg (10 mg/ml) for 30 minutes and stimulated for 6 hours with 10 ng/ml of LPS. Release of TNF-α, IL-6, and MIP-2 was measured by ELISA. *$P<0.05$.  

Downloaded from http://www.jci.org on January 1, 2018. https://doi.org/10.1172/JCI74572
high-affinity IgE receptor (FcεRI) by IgE and antigen was strongly inhibited (65% inhibition) following AT-10 F(ab′)2 treatment (Figure 5C). The Y304F (Y-to-F mutation at position 304 located in hFcγRIIA ITAM) was sufficient to abolish both the inhibitory signal induced by AT-10 F(ab′)2 (Figure 5B) and to restore degranulation (Figure 5C). The Y288F (first tyrosine of the ITAM) or Y281F (TM region-proximal tyrosine) did not induce such effects. In contrast, both ITAM tyrosine residues (Y288 and Y304) were required for cell activation following extensive aggregation of hFcγRIIA (independently of FcεRI triggering) as measured by stable Syk recruitment, absence of SHP-1 recruitment, and cell degranulation (Figure 5, D and E). Double and triple mutants of these tyrosine residues confirmed these results (Supplemental Figure 4, B–G).

Together, these findings demonstrate that hFcγRIIA can initiate an inhibitory signaling that has all the characteristics of bona fide ITAMI signaling, including sequential Syk–SHP-1 recruitment, inhibition of heterologous receptors (such as FcεRI or TLR4), and requirement for an intact ITAM motif. Furthermore, these data unveil different structural requirements for ITAM activating and ITAMI signals generated by hFcγRIIA.

Both hFcγRIIA R131 and H131 allotypes mediate ITAMI signaling. FcγRIIA exhibits a genetically determined polymorphism (FcγRIIA-R131 and FcγRIIA-H131), resulting in differential ability to bind IgG subclasses (12). To explore whether these 2 allotypes can induce ITAMI signaling, we established RBL-2H3 transfectants expressing either hFcγRIIA-R131 or hFcγRIIA-H131. In both transfectants, which expressed significant levels of these allotypes at their cell surface (Figure 4A and Figure 6A), targeting the receptor by AT-10 F(ab′)2, resulted in a similar ITAMI signature with Syk transient recruitment and SHP-1 stable recruitment (Figure 6B). Moreover, IgE-mediated degranulation of hFcγRIIA-R131′ or hFcγRIIA-H131′ RBL-2H3 transfectants was similarly inhibited by AT-10 F(ab′)2 treatment (93% and 82% inhibition, respectively) (Figure 6C). Overall, these data demonstrate that both FcγRIIA allotypes can induce ITAMI signaling and similarly inhibit cell activation.

hFcγRIIA-ITAMI signaling prevents IRAK-1–induced inflammatory responses. Leukocyte infiltration in the inflamed synovium, one of the hallmarks of severe RA, is linked to disease progression and characterized by exacerbated production of inflammatory cytokines and ROS (27). To explore whether hFcγRIIA-induced inhibitory signaling resulted in the modulation of leukocyte inflammatory response, we first analyzed the production of cytokines in LPS-stimulated THP-1–hFcγRIIA–R131+-CD14+ cells and in purified blood monocytes transfected or not with various siRNA and stimulated with 10 ng/ml of LPS. Pretreatment of THP-1–hFcγRIIA–R131+-CD14+ cells with AT-10 F(ab′)2 nearly abolished IL-8 secretion induced by LPS (Figure 7A). Silencing of the mRNA encoding hFcγRIIA, Syk, or SHP-1 significantly restored IL-8 production induced by LPS in these conditions (Figure 7A). Likewise,
pretreatment of purified human blood monocytes with AT-10 F(ab')2 significantly impaired the LPS-induced secretion of TNF-α, IL-6, and IL-8 independently of FcγRIIB, as a FCGR2B knockdown had no effect on AT-10–mediated inhibition in monocytes (data not shown). Again, siRNA-induced knockdown of the mRNAs encoding hFcγRIIA, Syk, or SHP-1 restored the LPS-induced production of these inflammatory cytokines (Figure 7B). Efficacy of siRNAs for FCGR2A and FCGR2B was verified by reverse transcriptase PCR (RT-PCR) in blood monocytes (Supplemental Figure 5). To further elucidate the hFcγRIIA inhibitory mechanism involved in the downregulation of responses to LPS, TLR4-signaling pathways were investigated. AT-10 F(ab')2 inhibited the activation and degradation of IL-1 receptor–associated kinase 1 (IRAK-1) and the phosphorylation of NF-κB (p65) induced by LPS in THP-1–hFcγRIIA-R131F-CD14+ cells (Figure 7C). This was associated with SHP-1 phosphorylation. Moreover, silencing of Syk or SHP-1 by

Figure 5. hFcγRIIA mediates inhibition that relies on the ITAM distal tyrosine. (A) hFcγRIIA constructs are schematically represented; their surface-expression levels after transfection into RBL-2H3 cells are shown compared with nontransfected cells (gray-shaded vs. open red histograms). (B) For ITAMI induction, RBL-2H3 transfectants were incubated at 37°C with AT-10 F(ab')2 (10 μg/ml) for indicated times; cell lysates were immunoprecipitated with AT-10 (IP: FcγRII) followed by immunoblotting with anti-Syk, anti–SHP-1, or anti-hFcγRIIA. The amounts of SHP-1 and Syk in lysates were analyzed in parallel by immunoblotting. (C) IgE-sensitized RBL-2H3 transfectants were incubated overnight at 37°C with AT-10 F(ab')2, and degranulation was triggered with DNP-HSA for 45 minutes. Net β-hexosaminidase release was determined. (D) For ITAMα induction, RBL-2H3 transfectants were incubated with AT-10 F(ab')2 for 30 minutes at 4°C, washed, and stimulated with anti-mouse κ chain F(ab’)2 for the indicated times at 37°C. Cells lysates were treated and analyzed as in B. (E) RBL-2H3 transfectants were incubated with AT-10 F(ab')2 (10 μg/ml) for 30 minutes at 4°C, and degranulation was triggered by anti-κ F(ab’)2 for 45 minutes at 37°C. In parallel, IgE-sensitized RBL-2H3 transfectants were treated as in C. *P < 0.05; n = 12.
siRNA restored the activation of IRAK-1 and the phosphorylation of p65, confirming that ITAMi signaling may control TLR-signaling effectors. Next, IRAK-1 was immunoprecipitated to explore the effect of ITAMi signaling on LPS-induced IRAK-1–TRAF-6 association and a possible interaction between IRAK-1 and SHP-1. Pretreatment of THP-1–hFcRIIA-R131+–CD14+ cells with AT-10 F(ab′)2 induced an interaction between SHP-1 and IRAK-1 and impaired the formation of the IRAK-1–TRAF-6 complex induced by LPS. Silencing of SHP-1 or of Syk by siRNA impaired the ITAMi-induced effects (Figure 7D).

These results demonstrate that hFcγRIIA-ITAMi signaling inhibits LPS-induced IRAK-1 activation, resulting in the blockade of NF-κB activation and in the dampening of inflammatory responses in monocytes (summarized in Figure 7E).

hFcγRIIA-ITAMi signaling regulates ROS production through inhibition of Vav-1 and Rac. Next, we examined whether hFcγRIIA-ITAMi signaling could modulate ROS production by primary human blood neutrophils that abundantly express hFcγRIIA and the glycosylphosphatidylinositol-linked (GPI-linked) hFcγRIIB, but neither hFcγRIIB nor hFcγRI (Figure 8A). As Vav-1 and the small GTPase Rac play key roles in the production of ROS (28, 29), we investigated the impact of hFcγRIIA ITAMi signaling on these molecules. Pretreatment of neutrophils with AT-10 F(ab′)2, inhibited both constitutive and FMLF-induced ROS production (Figure 8B). This was associated with impaired interactions between Rac and Vav-1 and between Rac and PKA (Figure 8C). As SHP-1 selectively dephosphorylates Vav-1 during inhibitory signaling induced by killer cell inhibitory receptors in NK cells (30), we next investigated whether hFcγRIIA-ITAMi–recruited SHP-1 may target Vav-1. AT-10 F(ab′)2 treatment induced a Vav-1–SHP-1 interaction (Figure 8D).

To explore whether hFcγRIIB may contribute to this inhibitory pathway, we used primary blood monocytes that, unlike human neutrophils, express this inhibitory receptor (Figure 8E). These cells use the same signaling pathway, leading to ROS production following fMLF stimulation. As expected, AT-10 F(ab′)2, inhibited ROS production in primary monocytes (Figure 8F). FCGR2B siRNA had no effect on this inhibition (Figure 8F and Supplemental Figure 5). In contrast, SHP-1 silencing by siRNA restored ROS production. As observed for neutrophils, pretreatment of monocytes with AT-10 F(ab′)2 inhibited the fMLF-induced interactions between Rac and Vav-1 and between Rac and PKA (Figure 8G) that correlated with the induction of a Vav-1–SHP-1 interaction (Figure 8H). Additionally, SHP-1 silencing by siRNA restored Rac–Vav-1 interaction and consequently Rac–PAK1 complex formation (Figure 8G). These data show that hFcγRIIA targeting by AT-10 F(ab′)2, independently of inhibitory hFcγRIIB, induces an ITAMi signaling that is responsible for the recruitment of SHP-1, leading, through inhibition of Vav-1, to blocking of Rac activation, resulting in a decrease of ROS production in human blood monocytes and neutrophils (Figure 8I).

Reverting synovial cell activation from RA patients by hFcγRIIA-ITAMi induction. RA is associated with an infiltration of blood cells and ROS production in the synovial compartment, all of which are responsible for tissue injury and disease severity (2). Neutrophils accounted for the majority (75%) of infiltrating cells in the synovium of RA patients, whereas monocytes were a minority (6%), with T cells accounting for the remaining cells. Infiltrating neutrophils expressed high levels of hFcγRIIA and GPI-linked hFcγRIIB and very low levels of hFcγRI and hFcγRIIB, whereas infiltrating monocytes expressed high levels of hFcγRI and hFcγRIIA and significant levels of hFcγRIIB and hFcγRII (Figure 9A). As expected, infiltrating T cells expressed no hFcγR. ROS are constitutively produced by infiltrating cells isolated from the synovial fluid of RA patients.
infiltrating cells, as revealed by reduced ROS production and increased association among Rac, Vav-1, and PAK-1 (Figure 9, B and C). These observations show that AT-10 F(\(ab\)\(^{\prime}\))\(_2\) treatment switches the constitutive inflammatory Fc\(\gamma\)RIIA-ITAM "activation" signaling into a "Fc\(\gamma\)RIIA-ITAMI" signaling in infiltrating cells from RA patients, thus reverting Rac activation and ROS production and opening new therapeutic avenues in this disease.

Discussion

Our data demonstrate that hFc\(\gamma\)RIIA (CD32A) can function as both an activating and an inhibitory receptor. By modifying the type of receptor engagement, one may switch the function of this dual activating/inhibitory receptor and use that property to revert the inflammatory phenotype of hFc\(\gamma\)RIIA-expressing cells, as we demonstrated for infiltrating cells from the synovial cavity of RA patients, thus reverting Rac activation and ROS production and opening new therapeutic avenues in this disease.
“ITAMI” configuration of hFcγRIIA that requires involvement of the tyrosine phosphatase SHP-1. ITAM-dependent recruitment of SHP-1 has been previously demonstrated following activation of FcεRI or hFcγRIIA (31, 32) and is thought in this case to act as a negative feedback loop regulating activation signals induced by their own receptors in an intrinsic retro-control mechanism. This differs substantially from the hFcγRIIA-ITAMI configuration in which SHP-1 acts toward a heterologous receptor. This configuration can be induced with AT-10 F(ab')2 even when receptors are already activated in vivo by ICs. This switch from an “ITAMA” to an “ITAMI” configuration in RA synovial fluid–infiltrating cells led to an inhibition of ROS production (Figure 10). This mechanism may explain the specific therapeutic effect following AT-10 F(ab')2 treatment that we observed in the mouse model of RA. Interestingly, hFcγRIIA blockade by small chemical inhibitors as antagonists attenuates arthritis (33). However, the inhibitory signal investigated in this study seems to rely on its passive blocking effect rather than on ITAMI signaling since, in contrast with ITAMI signaling (18), it failed to inhibit activation of heterologous receptors.

Human FcγRIIA exhibit a genetically determined polymorphism (hFcγRIIA-R131 and hFcγRIIA-H131) (12, 34), resulting in differential ability to recognize and be activated by human and murine IgG isotopes. The H131 allele has a moderate affinity for human IgG2 and a low affinity for murine IgG1, while the R131 allele has a low affinity for human IgG2, but a moderate affinity for murine IgG1 (9, 12). The current study is the first, to our knowledge, to demonstrate that targeting of either allele by AT-10 F(ab')2 is able to induce ITAMI signaling, indicating that hFcγRIIA polymorphism does not influence the antiinflammatory effect of anti-FcγRIIA antibodies. This approach could thus be used as a treatment for RA patients independently of FCGR2A polymorphisms.

Circulating autoantibodies are a prominent feature of RA, and joint tissue is frequently covered with ICs (3, 4). It has been clearly demonstrated that ITAM-bearing Fc receptors are crucial for arthritis development in mice. Indeed, mice lacking the FcRγ subunit that is required for the expression of activating mouse FcRs (FcRγ−/− mice) were resistant to K/BxN (35) and CAIA (15, 36, 37). In humans, hFcγRIIA, and more particularly, hFcγRI-A131, is associated with RA development (15). However, as mice do not express hFcγRIIA, the transgenic expression of hFcγRIIA was established to develop a mouse model relevant to the human RA disease (37).

We confirm here that transgenic mice expressing hFcγRIIA alone on a FcRγ−/− background were prone to developing arthritis. Importantly, for what we show for the first time that an inhibitory signal generated by the same receptor was effective in vivo, as treatment of CAIA in these mice by AT-10 or IV.3 F(ab')2 resulted in a significant reduction of inflammation and arthritic scores. These antibodies do not bind murine Fc-RIIB, excluding its contribution in these experiments. Interestingly, ICs formed by the interaction of disease-specific autoantibodies to citrullinated proteins with, for example, citrullinated fibrin, activate hFcγRIIA ITAMI, contributing to TNF-α production by macrophages (25). This activation process could be blocked by anti-hFcγRIIA F(ab')2 but neither by anti-hFcγRI nor anti-hFcγRII antibodies. Our data demonstrate that such a treatment not only alleviated hFcγRIIA-mediated disease, but also reduced the disease index significantly below what was observed in nontransgenic mice, revealing an inhibitory signal that acts on other activating receptor pathways.

RA inflammation involves the release of cytokines (1) and ROS (27). In synovial fluid–infiltrating cells from RA patients, anti-hFcγRII F(ab')2 targeting increased Syk recruitment to the receptor, which was rapidly followed by its disengagement and a stable recruitment of SHP-1. Activation of hFcγRIIA-ITAMI signaling on human monocytes and neutrophils resulted in the association of SHP-1 with major effectors (IRAK-1 and Vav-1) involved in cytokine and ROS production, respectively (38), thus allowing a pleiotropic inhibition of inflammatory cell activation.

The mechanism by which ITAM-bearing receptors mediate recruitment of SHP-1 was, however, unclear until now. Indeed, in previous studies using chimeric receptors made of the extracellular domains of FcεRI or hFcγRIIA and the intracellular domain of the FcRγ subunit (hFcεRI-FcRγ or hFcγRIIA-FcRγ, respectively), we failed to identify which tyrosine of the FcRγ ITAM was implicated in the inhibitory signal (21, 24). The present study using hFcγRIIA mutants allowed us to identify differential structural requirements between ITAMA and ITAMI signaling. Whereas ITAMA signaling required phosphorylation of both tyrosine residues of ITAM, ITAMI signaling required only the membrane-distal tyrosine (Y304). Interestingly, phosphorylation of the 2 FcεR ITAM tyrosines is required for stable association and full activation of Syk, whereas a monophosphorylated FcRγ ITAM allows only minimal association and activation of Syk (39, 40). In the light of these reports and based on our present findings, we suggest that hFcγRIIA ITAMI signaling starts with monophosphorylation of its ITAM, allowing a transient recruitment and minimal activation of Syk. This would permit phosphorylation and activation of SHP-1, followed by SHP-1 recruitment to the phosphotyrosine Y304 of the monophosphorylated ITAM, which remained accessible after Syk disengagement from
The receptor. This mechanism significantly differs from the classical ITAM signaling, in which dual tyrosine phosphorylation of the hFcγRIIA ITAM leads to stable recruitment of Syk and to its robust activation (Figure 10). The extent of receptor aggregation could be the critical parameter that determines a bias toward ITAMa or ITAMI signaling. Indeed, dimerization of FcRIIA was required for ITAMI signaling, since no signal was generated by monovalent engagement of the receptor (AT-10 Fab alone; not shown), whereas extensive aggregation of the receptor led to ITAMa signaling. This is also supported by published observations that a proportion of FcγRIIA is constitutively present as a dimer on the cell surface (41) and that monomeric IgG may stabilize these dimers (42). Similar observations were obtained for FcγRIIA in which 3G8 Fab′, but not Fab anti-FcγRII, can induce ITAMi signaling (24).

Because mAb AT-10 binds to both hFcγRIIA and hFcγRIIB, one may argue that the use of AT-10 anti-hFcγRII Fab′, on synovial fluid–infiltrating cells from RA patients may also engage inhibitory hFcγRIIB. If engaged, hFcγRIIB is nevertheless unlikely to account for the drastic downregulation of their inflammatory phenotype following AT-10 anti-hFcγRII Fab′, treatment, as indeed, only 6% of the cells were found to express hFcγRIIB (monocytes). Knockdown of FcγRIIB by siRNA in blood monocytes had no effect on ROS production, and hFcγRIIB was not expressed by THP-1 cells or by human neutrophils (75% of synovium-infiltrating cells), the receptor. This mechanism significantly differs from the classical ITAM signaling, in which dual tyrosine phosphorylation of the hFcγRIIA ITAM leads to stable recruitment of Syk and to its robust activation (Figure 10). The extent of receptor aggregation could be the critical parameter that determines a bias toward ITAMa or ITAMI signaling. Indeed, dimerization of FcRIIA was required for ITAMI signaling, since no signal was generated by monovalent engagement of the receptor (AT-10 Fab alone; not shown), whereas extensive aggregation of the receptor led to ITAMa signaling. This is also supported by published observations that a proportion of FcγRIIA is constitutively present as a dimer on the cell surface (41) and that monomeric IgG may stabilize these dimers (42). Similar observations were obtained for FcγRIIA in which 3G8 Fab′, but not Fab anti-FcγRII, can induce ITAMi signaling (24).

Because mAb AT-10 binds to both hFcγRIIA and hFcγRIIB, one may argue that the use of AT-10 anti-hFcγRII Fab′, on synovial fluid–infiltrating cells from RA patients may also engage inhibitory hFcγRIIB. If engaged, hFcγRIIB is nevertheless unlikely to account for the drastic downregulation of their inflammatory phenotype following AT-10 anti-hFcγRII Fab′, treatment, as indeed, only 6% of the cells were found to express hFcγRIIB (monocytes). Knockdown of FcγRIIB by siRNA in blood monocytes had no effect on ROS production, and hFcγRIIB was not expressed by THP-1 cells or by human neutrophils (75% of synovium-infiltrating cells), the receptor. This mechanism significantly differs from the classical ITAM signaling, in which dual tyrosine phosphorylation of the hFcγRIIA ITAM leads to stable recruitment of Syk and to its robust activation (Figure 10). The extent of receptor aggregation could be the critical parameter that determines a bias toward ITAMa or ITAMI signaling. Indeed, dimerization of FcRIIA was required for ITAMI signaling, since no signal was generated by monovalent engagement of the receptor (AT-10 Fab alone; not shown), whereas extensive aggregation of the receptor led to ITAMa signaling. This is also supported by published observations that a proportion of FcγRIIA is constitutively present as a dimer on the cell surface (41) and that monomeric IgG may stabilize these dimers (42). Similar observations were obtained for FcγRIIA in which 3G8 Fab′, but not Fab anti-FcγRII, can induce ITAMi signaling (24).

Because mAb AT-10 binds to both hFcγRIIA and hFcγRIIB, one may argue that the use of AT-10 anti-hFcγRII Fab′, on synovial fluid–infiltrating cells from RA patients may also engage inhibitory hFcγRIIB. If engaged, hFcγRIIB is nevertheless unlikely to account for the drastic downregulation of their inflammatory phenotype following AT-10 anti-hFcγRII Fab′, treatment, as indeed, only 6% of the cells were found to express hFcγRIIB (monocytes). Knockdown of FcγRIIB by siRNA in blood monocytes had no effect on ROS production, and hFcγRIIB was not expressed by THP-1 cells or by human neutrophils (75% of synovium-infiltrating cells), the receptor. This mechanism significantly differs from the classical ITAM signaling, in which dual tyrosine phosphorylation of the hFcγRIIA ITAM leads to stable recruitment of Syk and to its robust activation (Figure 10). The extent of receptor aggregation could be the critical parameter that determines a bias toward ITAMa or ITAMI signaling. Indeed, dimerization of FcRIIA was required for ITAMI signaling, since no signal was generated by monovalent engagement of the receptor (AT-10 Fab alone; not shown), whereas extensive aggregation of the receptor led to ITAMa signaling. This is also supported by published observations that a proportion of FcγRIIA is constitutively present as a dimer on the cell surface (41) and that monomeric IgG may stabilize these dimers (42). Similar observations were obtained for FcγRIIA in which 3G8 Fab′, but not Fab anti-FcγRII, can induce ITAMi signaling (24).

Because mAb AT-10 binds to both hFcγRIIA and hFcγRIIB, one may argue that the use of AT-10 anti-hFcγRII Fab′, on synovial fluid–infiltrating cells from RA patients may also engage inhibitory hFcγRIIB. If engaged, hFcγRIIB is nevertheless unlikely to account for the drastic downregulation of their inflammatory phenotype following AT-10 anti-hFcγRII Fab′, treatment, as indeed, only 6% of the cells were found to express hFcγRIIB (monocytes). Knockdown of FcγRIIB by siRNA in blood monocytes had no effect on ROS production, and hFcγRIIB was not expressed by THP-1 cells or by human neutrophils (75% of synovium-infiltrating cells),
The Journal of Clinical Investigation

ReseaR ch aR ticle

Figure 10. Proposed model for anti-hFcRIIA F(ab′)2 treatment in RA. (A) In healthy individuals, hFcRIIA exists in an ITAMi configuration with SHP-1 associated to its monophosphorylated ITAM as a possible result of hFcRIIA binding by low-affinity natural autoantibodies or of hFcRIIA inefficient triggering by monomeric circulating IgG. In this configuration, hFcRIIA ITAMi maintains a low level of cell activation for optimal homeostasis. (B) In RA patients, the presence of circulating rheumatoid factors results in the binding of high-avidity ICs to hFcRIIA, leading to stable aggregation of receptors, ITAMi signaling with stable recruitment of the kinase Syk to the doubly phosphorylated ITAM, cell activation, and production of inflammatory cytokines. This induces recruitment of additional inflammatory cells to the synovial cavity with further cell activation and production of ROS. (C) Treatment with anti-hFcRIIA F(ab′)2, or with IVlg can displace ICs from hFcRIIA and/or bind to free hFcRIIA. In any case, this leads to restoration of an ITAMi configuration of hFcRIIA with reversal of the inflammatory phenotype.

excluding involvement of this receptor in experiments performed with these cells. Supporting this conclusion, F(ab′)2 fragments of the hFcRIIA-specific mAb IV.3 (which does not bind to hFcRIIB) were sufficient to induce ITAMi signaling. These results together indicate that specific targeting of hFcRIIA may constitute a promising approach for RA treatment.

While crosslinking of the receptor by ICs induces cell activation, IVlg or anti-hFcRIIA F(ab′)2 fragments trigger a potent ITAMi signal, inhibiting various heterologous receptors. The ITAMi signaling had been previously demonstrated for FcγRI subunit–associated hFcRs, such as hFcµRI and hFcγRIIIA, or for DAP subunit–associated receptors, but not for a single-chain FcR such as hFcRIIA (16). Our data demonstrate that an ITAMi-containing single-chain receptor can also mediate efficient dual functions.

In summary, our study shows that hFcRIIA can act and be used as a switch that controls the outcome of an inflammatory response. We report that one can swap the hFcRIIA ITAMi signal observed in RA to an ITAMi signal reversing inflammatory responses. This opens new avenues for antibody-mediated antiinflammatory therapeutic approaches for RA based on hFcRIIA targeting.

Methods

Subjects. Synovial fluids from 7 patients with RA (without steroid and anti–CD20 treatments) were obtained during medical care. Blood from 10 healthy volunteers was collected.

Mice. Experiments were carried out on pathogen-free, 10- to 12-week-old female WT C57BL/6J, C57BL/6J hFcRIIA-transgenic mice (15) and FcγRIγ−/− C57BL/6J mice obtained from the Jackson Laboratory. FcγRIIAγ−/−FcγRIγ−− mice were obtained as described previously (43). Nontransgenic littermates served as controls.

Induction of arthritis. Arthritis was induced following the method of Terato et al. (44) using an arthritogenic mAb cocktail. Mice were injected i.v. with 5 mg/20 g of mouse of anti–collagen II (anti-CII) Ab (Chondrex, GENTAUR) followed by an i.p. injection of 50 μg LPS/20 g of mouse at day 3.

Cells and reagents. BMM from 6- to 8-week-old mice were obtained after a 7-day culture with CSF-1. RBL-2H3 cells expressing hFcRIIIA were maintained in DMEM supplemented with 10% FCS and 2 μg/ml puromycin (Invitrogen). THP-1–FcyRIIIA-R131+−CD14+ cell lines (provided by Novimmune) were maintained in RPMI-1640 supplemented with 10% FCS, 50 μM β-mercaptoethanol, 200 μg/ml Zeocin, 10 μg/ml blasticidin, and 2 μg/ml puromycin (Invitrogen). Human blood mononuclear cells were isolated by Ficoll-Hypaque density gradient centrifugation, and monocytes or neutrophils were purified by the Dynabeads Untouched Human Monocytes kit (Invitrogen) or by dextran sedimentation, respectively. Mouse anti-hFcγRII AT-10 mAb, which binds to an epitope located near or in the IgG-binding site (45), was purchased from Santa Cruz Biotechnology Inc. Mouse anti-hFcRIIIA IV.3 mAb, provided by C. Anderson (Department of Molecular Genetics, The Ohio State University, Columbus, Ohio, USA) (46, 47), was purified in house. AT-10, IV.3, and irrelevant control mAb (clone 320) were used as F(ab′)2, prepared as previously described (21, 48). IVlg (Privigen; 100 mg/ml) was purchased from CSL Behring Gmbh.

Cytokine measurements. After centrifugation (14,000 g, 10 minutes), THP-1–hFcRIIIA-R131+−CD14+ cells or blood monocyte supernatants were kept at −80°C until measurement. The presence of MCP-1, TNF-α, IL-6, and IL-8/MIP-2 in the supernatants was determined using ELISA kits (R&D Systems) according to the manufacturer’s instructions.
Immunoprecipitation and immunoblotting. Cells were solubilized in 1% digitonin-containing lysis buffer, and hFcRIIA cells were immunoprecipitated over 2 hours at 4°C with either protein G or AT-10 F(ab’), coupled to CNBr-activated sepharose 4B (Amersham Pharmacia). Proteins were resolved by sodium dodecylsulfate–10% polyacrylamide gel electrophoresis, transferred onto nitrocellulose membranes (Invitrogen), and immunoblotted with primary antibodies such as rabbit anti-FcγRI (Santa Cruz Biotechnology Inc.), anti-Syk (Santa Cruz Biotechnology Inc.), anti-Vav-1 (Cell Signaling Technology), anti-PAK1 (Cell Signaling Technology), anti-Rac (Santa Cruz Biotechnology Inc.), and anti-phospho–FcγRI (ECM Biosciences) followed by goat anti-rabbit IgG (Jackson ImmunoResearch Laboratories) coupled to horseradish peroxidase (HRP). Membranes were developed by enhanced chemiluminescence (ECL) treatment (Amersham Biosciences).

ROS measurement. Human monocytes or neutrophils (5 × 10⁵) were resuspended in 0.5 ml HBSS containing 10M luminol (Sigma-Aldrich) with AT-10 F(ab’), at 10 μg/ml or irrelevant 320 F(ab’), at 10 μg/ml for 30 minutes. Cells were stimulated with 1 μM fMLF (Sigma-Aldrich). Chemiluminescence was recorded with a luminometer (Bertold-Biolumat LB937). For BMN, cells were plated on Lab-Tek chambered coverglass slides (Nalge Nunc International), loaded with 50 μM DCFH-DA for 30 minutes, and stimulated with fMLF. After excitation at 488 nm, the green fluorescence of DCF was measured by confocal laser scanning microscopy (CLSM) (510-META, Carl Zeiss) equipped with a cell culture chamber at 37°C with a 5% CO₂ atmosphere.

cDNA constructs, transfection, RT-PCR, siRNA, degranulation, and chemotaxis assays. Details are described in Supplemental Methods.

Flow cytometry, histopathology, and immunohistochemistry. See Supplemental Methods for details, including antibodies used.

Statistics. Data analysis was performed using GraphPad Prism 5 software (GraphPad Software). Data are presented as the means ± SEM of at least 3 independent experiments. Comparisons were made by 2-tailed Student’s t test for independent samples. A P value of less than 0.05 was considered statistically significant.

Study approval. Patients gave written informed consent before participating in this study and were enrolled in the study after approval by the Hôpital Bichat Claude Bernard ethical committee. Data collection and analyses were performed anonymously. All animal protocols were approved by the French Agricultural Office and by an INSERM ethical committee.

Acknowledgments

The authors thank S. Benadda for confocal analyses; J. Bex-Coudrat, N. Ialy-Radio and A. Bouhalaïfa for animal care; and N. Quellard and B. Fernandez for histology. This work was supported by grants from Agence Nationale de la Recherche (ANR grants MIEN-2009 and BLANC International-2012) and by LabEx Inflamex. S.B. Mkaddem was supported by a grant from the French Foundation ARC (PDF20100601037).

Address correspondence to: Renato Monteiro, INSERM UMR 1149, Faculté de Médecine Paris Diderot – Site Xavier Bichat – 16, Rue Henri Huchard, Paris 75018 Cedex 18, France. Phone: 33.1.5727.7755; E-mail: renato.monteiro@inserm.fr.


37. Van de Velde NC, Mottram PL, Powell MS, Lim BS, Holmdahl R, Hogarth PM. Transgenic mice expressing human FcγRIIA have enhanced sensitivity to induced autoimmune arthritis as well as elevated Th17 cells. Immunol Lett. 2010;130(1–2):82–88.


